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Abstract
Childhood maltreatment (CM) is all too frequent among western societies, with an estimated 
prevalence of 10 to 15%. CM associates with increased risk of several psychiatric disorders, and 
therefore represents a worrying public and socio-economic burden. While associated clinical 
outcomes are well characterized, determining by which mechanisms early-life adverse experiences 
affect mental health over the lifespan is a major challenge. Epigenetic mechanisms, in particular 
DNA methylation, represent a form of molecular memory that may modify brain function over 
extended periods of time, as well as serve as a bio-marker of behavioral phenotypes associated 
with CM. Here, we review human studies suggesting that DNA methylation is a crucial substrate 
mediating neurobiological consequences of CM throughout life, thereby potentiating maladaptive 
behavioral patterns and psychopathological risk.
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Introduction
Children in our society are all too often subjected to maltreatment, which is a global 
problem of significant proportion affecting children of all races and socio-economic 
backgrounds [1]. It is estimated that over 30% of adult psychopathology is directly related to 
childhood maltreatment (CM), including but not limited to parental neglect, physical, sexual, 
and psychological abuse [2–4]. In extension to predicting psychiatric illness, CM has been 
associated with chronic forms of these pathologies, poor clinical course, greater incidence of 
hospitalization, increased comorbidity and reduced responsiveness to pharmacotherapy [5–
8].
An effort to gain insight into the mechanisms through which CM interacts with an 
individual’s biological make-up to trigger psychopathology has pointed towards the 
emerging field of behavioral epigenetics. Epigenetic modifications refer to the collective 
chemical and physical alterations of the genome that regulate the activity of genes in a time- 
and cell-dependent manner [9]. One of the most studied epigenetic marks is DNA 
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methylation, which mostly refers to the covalent addition of a methyl group to cytosines, 
often followed by a guanine (CpG dinucleotide). Methylation of cytosine has been 
associated with a variety of molecular events (including the modulation of DNA binding by 
transcription factors, or the recruitment of methyl-CpG binding proteins), and classically 
leads to chromatin condensation and transcriptional repression [10]. A majority of studies to 
date have focused on methylation of CpG sites in gene promoter regions. For additional 
information on molecular mechanisms of DNA methylation, as well as for methodological 
considerations, we refer the reader to recent exhaustive reviews [11–13].
A major challenge in the field of CM is to understand how early-life experiences can affect 
behavior and mental health outcomes over the lifespan. Epigenetic mechanisms, in particular 
DNA methylation, represent a form of cerebral plasticity that has the potential to modify 
gene expression over extended periods of time. Furthermore, while epigenetic processes may 
potentially occur throughout life, it has been proposed that early development represents a 
particularly sensitive period to epigenetic modification of the genome [14]. Within this 
framework, the present mini-review will emphasize the biological memory of CM embedded 
into the genome and its relation to stress related psychopathology [15–17]; what we refer to 
as the epigenetic memory hypothesis. We will focus our analysis on DNA methylation, by 
far the most studied epigenetic substrate linking early-life events with lifelong mental health.
HPA Axis
The most extensively investigated and reviewed gene in epigenetic studies of CM appears to 
be the glucocorticoid receptor (GR) [18]. Much of excitement surrounding this system arose 
from i) animal findings pointing towards differential DNA methylation as a result of early-
life variations in maternal care [19], as well as ii) dysfunctional hypothalamic-pituitary-
adrenal (HPA) axis responses to stress in humans with a history of CM [20, 21]. Building on 
these findings, our group was the first to provide evidence for an interaction between early-
life adversity and the human epigenome [22]. Briefly, DNA methylation of 2 CpG sites in 
the exon 1F promoter region of the GR gene was increased in suicide completers with a 
history of CM as compared to non-abused suicidees, as well as healthy controls. At the 
transcriptomic level, this resulted in reduced GR expression. Additional in vitro experiments 
focused on the promoter region where differential DNA methylation occurred as a function 
of CM. Results showed that low DNA methylation in this region leads to decreased 
transcriptional activation by the transcription factor NGFI-A, as well as decreased DNA 
occupancy by NGFI-A, strongly suggesting a molecular mechanism whereby CM may 
program GR expression.
Following this initial study, increased DNA methylation in the GR gene as a result of CM 
has been consistently associated with altered GR expression or stress reactivity across a 
variety of behavioral phenotypes (see [23–26] for recent reviews). Furthermore, consistent 
results have been obtained in both brain and peripheral tissues, thus establishing GR as a 
promising candidate gene for use as a biomarker of CM [26].
In addition to studies focusing exclusively on GR, epigenetic associations between GR and 
the monoamine oxidase A (MAOA) gene were assessed in a Swedish cohort of depressed 
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subjects with a history of early life adversity [27]. MAOA is of particular importance in 
psychiatric disorders as it plays a key role in the degradation of neurotransmitters such as 
noradrenaline, dopamine and serotonin (5-HT). One specific type of adversity, namely early 
parental death, was associated with hypermethylation of the NR3C1 gene proximal to an 
NGFI-A biding site, as assessed in saliva samples. A regression analysis revealed that this 
association may be mediated by a well-characterized genetic polymorphism in the MAOA 
promoter, therefore suggesting the involvement of both gene x gene and gene x environment 
interactions.
Activity of the HPA axis is tightly controlled by multiple regulatory mechanisms. At the 
intracellular level, FKBP5 represents a negative feedback loop: the expression of FKBP5 is 
stimulated by GR, while this protein functionally inhibits GR signaling. Independent groups 
have identified an interaction between several FKBP5 single nucleotide polymorphisms 
(SNPs) and a history of CM in PTSD, depression, and suicide attempts [28–30]. Recently, a 
functional SNP has been identified at a glucocorticoid response element in the FKBP5 intron 
2 that moderates the relationship between CM and adult PTSD [31]. Interestingly, 
individuals carrying the risk allele in intron 2, and with a history of CM, were shown to 
display decreased methylation in FKBP5 intron 7. Furthermore, intron 7 DNA methylation 
appeared to be regulated by glucocorticoid levels, and influenced FKBP5 activity.
Altogether, several genes and neuronal pathways are likely epigenetically reprogrammed by 
CM to alter HPA axis and stress responses over the lifespan.
Serotonin
The serotonergic system has been extensively investigated in its relation to early-life induced 
epigenetic regulation and psychiatric disorders. The most highly investigated gene being the 
serotonin transporter (SLC6A4), involved in neurotransmitter reuptake at serotonergic 
synapses. Early evidence has pointed to an interaction between 5-HTTLPR, a functional 
polymorphism in the promoter region of the SLC6A4 gene, and psychosocial stressors in 
conferring a risk for depression [32]. Although some later studies failed to replicate previous 
findings of genome x environment interactions between the SLC6A4 gene, adversity, and 
depression [33], there is still considerable support for this relationship [34]. In a recent series 
of investigations performed in the Iowa Adoptee Sample, methylation of the promoter region 
of the SLC6A4 gene was linked to a family history of CM, including physical and sexual 
abuse [35]. While no significant association emerged between specific CpG loci methylation 
and CM, overall DNA methylation was significantly increased across the promoter region 
for abused, in comparison to non-abused, males. This was in contrast to females, where two 
loci were found significantly hyper-methylated for those who had experienced CM. 
Replicating prior findings in a non-overlapping cohort of females, the authors validated that 
CM still associated with higher levels of SLC6A4 methylation [36]. Furthermore, in 
subsequent studies, epigenetic patterns of this gene were suggested to represent a 
mechanism linking CM to antisocial personality disorder (ASPD) symptoms. The same 
group of investigators discovered an interaction between parental history of 
psychopathology and CM as a predictor of the intensity of SLC6A4 DNA methylation and 
the risk of ASPD symptomology [37]. Finally, the authors aimed at determining how DNA 
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methylation impacts gene expression, and whether other non-promoter regions of the 
SLC6A4 gene served as additional candidates for gene x environment interactions [38]. The 
analysis identified two methylation sites that associated with variant-specific expression, as 
well as one site that associated with global SLC6A4 expression. Given the above studies, the 
relevance of SLC6A4 methylation on pre-treatment characteristics, and treatment outcome 
of depression are brought into question. Kang et al. [39] determined that SLC6A4 promoter 
DNA methylation status as a function of CM was significantly associated with worse pre-
treatment clinical presentation of depression, including severer symptomology, higher 
perceived stress, and an increased family history of psychopathology. Interestingly, the type 
of abuse (physical versus sexual) determined methylation site, while higher methylation at 
specific sites predicted both higher scores on tests of disability and lower scores on quality 
of life assessments. These data therefore suggest the possibility of interactive relationships 
between the type of childhood adversity, site of methylation, and clinical outcome.
Additional studies have focused on addressing the role of SLC6A4 DNA methylation and in 
vivo measures of serotonin synthesis (using positron emission tomography) in childhood 
physical aggression. Wang and colleagues [40] followed a longitudinal sample of adult 
males who showed significant levels of high childhood-limited aggression (C-LHPA), a 
phenotype associated with early-life adversity, and compared methylation patterns in T cells 
and monocytes of these males to controls. The authors found increased methylation at 4 
CpG sites in C-LHPA, which negatively correlated with in vivo levels of brain serotonin 
synthesis in the orbitofrontal cortex.
BDNF
There is evidence to support an interaction between 5-HT and brain-derived neurotrophic 
factor (BDNF) in guiding the development and plasticity of neurocircuits that regulate 
affective behaviors [41]. In a large population-based cohort study [42], two polymorphisms 
in the SLC6A4 and BDNF genes (5-HTTLPR and Val66Met, respectively) interacted with 
an unfavourable early environment to predict depressive symptomology. Depressive 
symptomology was most common in carriers of either the ll + Met or the ss/sl + Val/Val 
genotypes in the presence of a history of early-life adversity.
BDNF may also play an important role in energy homeostasis and food intake, thus 
representing a theoretically supported candidate gene in the pathophysiology of eating-
disorders [43]. In a recent study by Thaler et al. [44], a significant increase in methylation at 
specific CpG sites of the BDNF promoter was observed in a bulimia nervosa group as 
compared to normal eaters. A significant interaction effect was also observed between 
borderline personality disorder (BPD), CM, and methylation levels of the BDNF gene. 
Similar interactions were observed between bulimia nervosa, BPD and DNA methylation for 
the dopamine D2 receptor [45], suggesting that several neuronal networks may be affected. 
While methylation levels did not differ between bulimia and normal eaters, there was a slight 
increase in methylation of the D2 receptor in bulimics with BPD, as well as those who 
reported a history of childhood sexual abuse. Further investigating the BPD phenotype, 
Perroud et al. [46] explored the effects of psychotherapy on BDNF methylation levels. Prior 
to treatment, BPD subjects had a higher baseline BDNF methylation status as compared to 
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controls. In addition, a positive correlation was observed between the incidence rate of 
childhood trauma and methylation status in the BPD patients. BDNF methylation status was 
reassessed following a 4-week course of intensive dialectical behavior therapy, during which 
responders showed a decrease in methylation status over time. Additional studies will be 
necessary to further assess the appealing possibility that, in addition to pharmacotherapies 
and life experiences, psychotherapy might also associate with epigenetic plasticity.
Genome-wide studies
While hypothesis-driven approaches provide insight into the role that specific genes play in 
psychopathology, epigenetic reprogramming as a result of early-life adversity may occur on 
a much larger scale. As such, genome-wide studies seem better equipped to investigate 
disorders of complex genetic and epigenetic heterogeneity. Such methodological approaches 
allows for a more comprehensive overview of the molecular pathways potentially involved, 
and of the relationships between specific methylation sites and nearby genomic regions.
Moving away from a GR centered locus, our group recently broadened our explorations in 
the human brain hippocampus to a 6.5 million base pair region surrounding the GR [47], and 
to the genome-wide level [48] (using immuno-precipitation of methylated DNA and 
hybridization to custom-designed promoter arrays, MeDIP-chip). The latter study identified 
362 sites that were differentially methylated in suicide completers with a history of CM 
compared to psychiatrically normal controls, 248 of which were hypermethylated and 114 
hypomethylated [48]. Differentially methylated sites followed a non-random distribution and 
were clustered in specific genomic regions, suggesting wide reprogramming of the 
epigenome. Furthermore, fluorescence-assisted cell sorting using an antibody raised against 
the neuron specific protein Neu-N, allowed us to separate neuronal versus non-neuronal 
nuclear fractions, and revealed that most CM-associated DNA methylation changes occurred 
in neurons [48]. Highlighted sites included genes involved in neuronal plasticity: histone 
cluster 2, H2ab (HIST2H2AB); nuclear receptor subfamily 1, group D, member 1 (NR1D1); 
and amyotrophic lateral sclerosis 2 (ALS2), with DNA methylation level in the ALS2 
promoter region displaying functional effects on gene expression in vitro. Thus, these 
studies provide additional evidence supporting the hypothesis that CM leads to functionally 
relevant, genome-wide and cell-type specific reprogramming of the epigenome.
In addition to post-mortem brain analyses, researchers have also assessed epigenetic 
consequences of CM in peripheral samples. One such study characterized methylation 
patterns in peripheral blood samples of 14 institutionalized and 14 children raised by their 
biological parents [49]. Of the 26,214 sites tested (using the Infinium 27 array), 914 were 
differentially methylated in the two groups. These differences were mostly due to increased 
DNA methylation in the genomes of institutionalized children. In another genome-wide 
study [50], salivary specimens were analyzed in 96 maltreated children who were removed 
from their parents due to neglect or CM, in comparison to 96 matched controls. The analysis 
found 2868 CpG sites that showed significantly different methylation values between 
maltreated children and controls. The next level of inquiry then, is to question whether 
whole-genome epigenetic reprogramming in response to CM could predict dimensional 
ratings of childhood psychiatric disorders. Weder et al. [51] aimed to address this difficult 
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question using saliva-derived DNA in 94 maltreated and 96 healthy non-traumatized 
controls, while also assessing child depressive symptomology via the Mood and Feelings 
Questionnaire (MFQ). Methylation values at CpG sites in 3 genes significantly predicted 
depression scores, beyond the effects of CM: DNA Binding Protein Inhibitor ID-3 (ID3); 
Glutamate Receptor, Ionotropic N-methyl-D-aspartate (NMDA) 1 (GRIN1); and Tubulin 
Polymerization Promoting Protein (TPPP). In a follow-up analysis to investigate the impact 
of CM on DNA methylation of these 3 genes, all main effects reached significance while no 
significant interaction was observed.
While these studies have focused primarily on effects of CM on epigenetic programing 
early-on in life, other genome-wide studies have performed similar investigations at latter 
points in development. In the study by Essex et al., DNA methylation was investigated in 
buccal epithelial cells obtained from adolescents whose parents themselves experienced high 
levels of stress earlier in their child’s life [52]. Differential methylation was observed as a 
function of parental stress, child’s sex, and maternal versus paternal stress. Specifically, 
maternal and paternal stress resulted in 139 and 31 differentially methylated CpG sites, 
respectively. Parental stress resulted in differential methylation of the protein kinase N1 
(PKN1) gene promoter in boys, and the FAM172A (family with sequence similarity 172, 
member A; also known as C5orf21) gene promoter in girls. In another study by Suderman et 
al., methylation profiles of 40 males in a 1958 British Birth cohort were compared between 
those with and without a history of CM [53]. 20,000 genes and 489 microRNAs were 
analyzed by MeDIP-chip. The result of their investigation revealed 997 differentially 
methylated gene promoters, 311 of which were hyper-methylated and 686 hypo-methylated. 
Functionally, these genes have implications in cell signaling cascades related to development 
and transcriptional regulation. Abuse-associated differential methylation was found in 39 
microRNA genes; among these, hyper-methylation in 6 microRNA genes associated with 
hypo-methylation in downstream gene targets. Lastly, the metalloproteinase gene (PM20D1) 
displayed abuse-associated differential methylation that withstood validation and replication 
in an additional 27 males.
Because epigenetic modifications as a result of CM could disrupt complex physiological 
systems involved in stress regulation and behavioral regulation, researchers also explored 
epigenetic patterns in PTSD populations. In the study by Mehta et al. [54], expression 
microarray profiles revealed a total of 303 transcripts differentially expressed between PTSD 
subjects with a history of CM and controls. Meanwhile, 244 transcripts showed differential 
expression between PTSD subjects lacking a history of CM and control samples. 
Interestingly, an overlap of only 14 transcripts (2%) was found between these 2 gene lists, 
suggesting dissociable biomarkers for the PTSD phenotype in the presence and absence of a 
history of CM. Illumina 450K arrays were then used to assess whether gene expression 
changes associated with DNA methylation differences. At least one CpG site was 
differentially methylated in 69.3% of the transcripts specific to PTSD with a history of CM, 
while only 33.6% of the transcripts specific to PTSD without CM satisfied this requirement. 
When the criteria selectivity was increased to methylation of 5 or more CpG sites, the 
difference was accentuated to 11.7% compared with 0.8%. These results suggest that distinct 
biological pathways may be perturbed in clinical PTSD populations with and without a 
Lutz et al. Page 6
Curr Pharm Des. Author manuscript; available in PMC 2017 February 06.
CIHR A
uthor M
an
u
script
CIHR A
uthor M
an
u
script
CIHR A
uthor M
an
u
script
history of CM, with epigenetic adaptations being more prominent in the group of CM 
victims.
Finally, CM-induced epigenetic modifications have also started being addressed in the 
context of addictive disorders, and as a function of ethnicity. Zhang et al. performed a 
methylome analysis in African and European Americans with or without a history of CM, 
and with or without a diagnosis of alcohol dependence [55]. In European Americans, CM 
resulted in several sites of increased DNA methylation in both alcohol dependent and non-
dependent subjects that had a history of CM. In African Americans, CM-associated DNA 
methylation changes in dependent patients were not observed in non-dependent controls, 
suggesting interactive effects between ethnicity, clinical status, and epigenetic plasticity.
Altogether, recent data suggest that CM-induced DNA methylation changes at specific 
genes, in both peripheral and brain tissues, have major physiological implications for stress 
regulation, neural plasticity, and neurodevelopment.
Future directions
While the present review has attempted to highlight available human data indicating 
potential mechanisms through which the epigenome may represent a long lasting imprint of 
childhood adversity, the complexities of biological processes mediating this relationship 
have only begun to be unraveled. Several lines of converging evidence direct us towards 
DNA methylation as a potential epigenetic mechanism through which CM may exert long 
lasting effects on gene expression and human behavior. Nevertheless, this rapidly evolving 
field of investigation faces numerous key methodological limitations and challenges. Among 
these, we need to better understand at the molecular level how exposure to adversity results 
in differential methylation. Within this line, animal models should be instrumental in 
determining which epigenetic reprogramming events truly contribute to the emergence of 
behavioral dysregulation, or merely represent epiphenomenons (i.e. the difficult question of 
causality).
Researchers will also have to determine whether or not different forms of maltreatment 
trigger specific methylation patterns and neurobiological alterations [56], an issue that 
remains debated. Developmental timing [57] and cell-specificity [58] of CM-induced DNA 
methylation adaptations remain also largely unknown. In fact, there is some evidence that 
the timing of CM might be important in determining the severity of epigenetic alterations 
[14]. It is possible that abuse occurring earlier in development might lead to severer 
consequences, suggesting that there may be a critical period where CM exerts its greatest 
effects on the human epigenome [59]. As such, researchers have begun to incorporate 
epigenetics assessments into longitudinal studies, so as to tap into the developmental course 
of CM on the epigenome. Another major consideration is whether genome-wide epigenetic 
consequences of CM in peripheral tissue are reflective of plastic changes in the CNS [60–
63]. Advances in cell sorting methods, as well as DNA collection from multiple tissue 
sources will allow us to gain a more comprehensive overview of CM-dependent epigenetic 
memory [58], at the “body-wide” level. Finally, studies should standardize methodologies to 
improve comparison of findings and facilitate multicenter initiatives.
Lutz et al. Page 7
Curr Pharm Des. Author manuscript; available in PMC 2017 February 06.
CIHR A
uthor M
an
u
script
CIHR A
uthor M
an
u
script
CIHR A
uthor M
an
u
script
In conclusion, we summarized in the present review our current knowledge on epigenetic 
mechanisms mediating lifelong consequences of early-life adversity in human. As the 
understanding of molecular epigenetic processes is rapidly progressing, future studies will 
likely provide deeper insight on the crucial role of DNA methylation, in combination with 
other epigenetic marks and mechanisms, at the interface of genes, life experiences, 
behavioral regulation and mental health.
Abbreviations
ASPD antisocial personality disorder
ALS2 amyotrophic lateral sclerosis 2
BDNF brain-derived neurotrophic factor
BPD borderline personality disorder
CM childhood maltreatment
FAM172A family with sequence similarity 172, member A (also known as C5orf21)
GR glucocorticoid receptor
GRIN1 Glutamate Receptor, Ionotropic N-methyl-D-aspartate (NMDA) 1
HPA axis hypothalamic-pituitary-adrenal axis
HIST2H2ABhistone cluster 2, H2ab
ID3 DNA Binding Protein Inhibitor ID-3
MAOA monoamine oxidase A
NR1D1 nuclear receptor subfamily 1, group D, member 1
PET positron emission tomography
PKN1 protein kinase N1
SLC6A4 serotonin transporter
SNP single nucleotide polymorphisms
TPPP Tubulin Polymerization Promoting Protein
5-HT serotonin
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